Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of December 2013. The registrant is a foreign private issuer based in Australia. The filing primarily discloses a new issue of securities and the application for quotation of those securities on the Australian Securities Exchange (ASX).
Key Financial Metrics and Capital Structure
The filing details a specific capital raise event rather than providing comprehensive financial statements (revenue, profit, or cash flow are not reported in this document).
- Securities Issued: 181,750 Ordinary Shares.
- Consideration: The issue consisted of two tranches: 100,000 shares issued for AUD$33,000 cash consideration, and 81,750 shares issued for nil cash consideration.
- Purpose: Exercise of unlisted options (specifically classes PBTAB and PBTAQ).
- Total Quoted Capital: Following the issue, the total number of Ordinary Shares quoted on the ASX is 416,481,096.
- Unquoted Securities: The company holds 25,969,118 unlisted options across various classes (PBTAA through PBTAE) with exercise prices ranging from $Nil to AUD$1.04 and expiry dates between 2014 and 2018.
Material Changes Versus Prior Period
The primary material change is the increase in the company's issued share capital by 181,750 shares due to the exercise of options on December 20, 2013. The filing notes that the company has complied with Chapter 2M of the Corporations Act and Section 674 regarding the issue of these shares without a disclosure document to investors.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, or an outlook for future periods. It is a regulatory disclosure regarding a specific corporate action. The filing includes standard warranties to the ASX that the issue complies with the law, is not for an illegal purpose, and that no "excluded information" requiring disclosure exists as of the filing date.
Investor Verification Checklist
- Verify the total number of shares on issue (416,481,096) against the company's latest annual report to confirm the dilution impact.
- Review the terms of the unlisted options (25,969,118 total) to assess potential future dilution, noting the mix of nil and paid exercise prices.
- Confirm the remaining placement capacity under ASX Rules 7.1 and 7.1A, which the filing calculates as 54,539,660 and 40,958,327 shares respectively.
- Note that the filing text does not provide revenue, profit, or cash flow data; refer to the most recent Form 20-F for financial performance.